These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 16969296

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements.
    Fredericks S, Jorga A, MacPhee IA, Reboux S, Shiferaw E, Moreton M, Carter ND, Holt DW, Johnston A.
    Clin Transplant; 2007; 21(2):252-7. PubMed ID: 17425754
    [Abstract] [Full Text] [Related]

  • 3. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
    Zheng H, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP, Webber S, Ristich J, Dauber J, Iacono A, Grgurich W, Zaldonis D, McDade K, Zhang J, Burckart GJ.
    J Clin Pharmacol; 2004 Feb; 44(2):135-40. PubMed ID: 14747421
    [Abstract] [Full Text] [Related]

  • 4. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A.
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [Abstract] [Full Text] [Related]

  • 5. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
    Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Büchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P.
    Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
    [Abstract] [Full Text] [Related]

  • 6. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS.
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [Abstract] [Full Text] [Related]

  • 7. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N, Aghdaie MH, Behzad-Behbahanie A, Geramizadeh B, Behzadi S, Malekhoseinie SA, Raisjalal GH, Rahsaz M, Pourgholami A, Sagheb F.
    Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
    [Abstract] [Full Text] [Related]

  • 8. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients.
    Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, Tosun O, Gultekin M, Luleci G.
    Transplant Proc; 2006 Jun; 38(5):1290-2. PubMed ID: 16797284
    [Abstract] [Full Text] [Related]

  • 9. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms.
    Li D, Gui R, Li J, Huang Z, Nie X.
    Transplant Proc; 2006 Nov; 38(9):2850-2. PubMed ID: 17112846
    [Abstract] [Full Text] [Related]

  • 10. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemont L.
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [Abstract] [Full Text] [Related]

  • 11. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors.
    Wang J, Zeevi A, McCurry K, Schuetz E, Zheng H, Iacono A, McDade K, Zaldonis D, Webber S, Watanabe RM, Burckart GJ.
    Transpl Immunol; 2006 Jan; 15(3):235-40. PubMed ID: 16431292
    [Abstract] [Full Text] [Related]

  • 12. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L, Aguilera-García I, Docobo-Pérez F, Alamo-Martínez JM, Pareja-Ciuró F, Nuñez-Roldán A, Gómez-Bravo MA, Bernardos-Rodríguez A.
    Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
    [Abstract] [Full Text] [Related]

  • 13. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
    Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK.
    Transplantation; 2003 Oct 27; 76(8):1233-5. PubMed ID: 14578760
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
    Mendes J, Martinho A, Simoes O, Mota A, Breitenfeld L, Pais L.
    Transplant Proc; 2009 Apr 27; 41(3):840-2. PubMed ID: 19376366
    [Abstract] [Full Text] [Related]

  • 17. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T.
    Transplant Proc; 2005 May 27; 37(4):1730-2. PubMed ID: 15919447
    [Abstract] [Full Text] [Related]

  • 18. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K.
    Pharmacogenet Genomics; 2008 May 27; 18(5):413-23. PubMed ID: 18408564
    [Abstract] [Full Text] [Related]

  • 19. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
    Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q, Wang W.
    Transplant Proc; 2005 May 27; 37(1):178-81. PubMed ID: 15808586
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.